{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:06:06Z","timestamp":1794474366209,"version":"4.9.1"},"publisher-location":"Berlin, Heidelberg","reference-count":34,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642544897","type":"print"},{"value":"9783642544903","type":"electronic"}],"license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-3-642-54490-3_24","type":"book-chapter","created":{"date-parts":[[2014,4,22]],"date-time":"2014-04-22T05:36:51Z","timestamp":1398145011000},"page":"393-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Temsirolimus"],"prefix":"10.1007","author":[{"given":"Michael","family":"Schulze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Zaccagnini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dogu","family":"Teber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens J.","family":"Rassweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,23]]},"reference":[{"key":"24_CR1","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1200\/JCO.2005.07.114","volume":"23","author":"N Aass","year":"2005","unstructured":"Aass N, De Mulder HM, Mickisch GHJ et al (2005) Randomized phase II\/III trial of interferon alfa-2a with and without 13- cis \u2013retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EOTORC 30951). J Clin Oncol 23:4172\u20134178","journal-title":"J Clin Oncol"},{"issue":"18","key":"24_CR2","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1517\/14656566.7.18.2481","volume":"7","author":"DT Alexandrescu","year":"2006","unstructured":"Alexandrescu DT, Dasanu CA (2006) Kidney cancer therapy: new perspectives and avenues. Expert Opin Pharmacother 7(18):2481\u20132493","journal-title":"Expert Opin Pharmacother"},{"key":"24_CR3","doi-asserted-by":"crossref","unstructured":"Ansell SM et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. A phase 2 trial in the North Central Cancer Treatment Group. Cancer 113(3)","DOI":"10.1002\/cncr.23580"},{"key":"24_CR4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909\u2013918","journal-title":"J Clin Oncol"},{"key":"24_CR5","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10637-005-1444-0","volume":"23","author":"SM Chang","year":"2005","unstructured":"Chang SM et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357\u2013361","journal-title":"Invest New Drugs"},{"issue":"9","key":"24_CR6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","volume":"95","author":"I Duran","year":"2006","unstructured":"Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148\u20131154","journal-title":"Br J Cancer"},{"issue":"9","key":"24_CR7","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2165\/00003495-200767090-00002","volume":"67","author":"B Escudier","year":"2007","unstructured":"Escudier B (2007) Advanced renal cell carcinoma: current and emerging management strategies. Drugs 67(9):1257\u20131264","journal-title":"Drugs"},{"issue":"9605","key":"24_CR8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103\u20132111","journal-title":"Lancet"},{"key":"24_CR9","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2005.23.622","volume":"23","author":"E Galanis","year":"2005","unstructured":"Galanis E et al (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294\u20135304","journal-title":"J Clin Oncol"},{"key":"24_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","volume":"11","author":"DA Guertin","year":"2005","unstructured":"Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11:353\u2013361","journal-title":"Trends Mol Med"},{"key":"24_CR11","doi-asserted-by":"crossref","unstructured":"Hess G, Verhoef G et al (2008) Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator\u2019s choice therapy. In: 44th annual meeting of the American Society of Clinical Oncology (ASCO)","DOI":"10.1200\/jco.2008.26.15_suppl.8513"},{"key":"24_CR12","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","volume":"12","author":"M Hidalgo","year":"2006","unstructured":"Hidalgo M, Buckner JC, Erlichman C et al (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5\u00a0days every 2\u00a0weeks to patients with advanced cancer. Clin Cancer Res 12:5755\u20135763","journal-title":"Clin Cancer Res"},{"key":"24_CR13","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356:2271\u20132281","journal-title":"N Engl J Med"},{"key":"24_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E et al (2007) Cancer statistics, 2007. CA Cancer J Clinic 57:43\u201366","journal-title":"CA Cancer J Clinic"},{"issue":"8","key":"24_CR15","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/ncponc0901","volume":"4","author":"JMG Larkin","year":"2007","unstructured":"Larkin JMG, Chowdhury S, Gore ME (2007) Drug insight: advances in renal cell carcinoma and the role of target therapies. Nat Clin Pract Oncol 4(8):470\u2013479","journal-title":"Nat Clin Pract Oncol"},{"key":"24_CR16","first-page":"1362","volume-title":"Cancer: principles and practice of oncology","author":"WM Linehan","year":"2001","unstructured":"Linehan WM, Zbar B, Bates SE et al (2001) Cancer of the kidney and ureter. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott Williams & Wilkins, Philadelphia, pp 1362\u20131396"},{"key":"24_CR17","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ceb.2005.02.008","volume":"17","author":"DE Martin","year":"2005","unstructured":"Martin DE, Hall MN (2005) The expanding TOR signaling network. Curr Opin Cell Biol 17:158\u2013166","journal-title":"Curr Opin Cell Biol"},{"issue":"35","key":"24_CR18","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Bukowsky RM (2006) Targeted therapy for metastatic renal carcinoma. J Clin Oncol 24(35):5601\u20135608","journal-title":"J Clin Oncol"},{"key":"24_CR19","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Figlin RA, Hutson TE et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). In: 44th annual meeting of the American Society of Clinical Oncology (ASCO)","DOI":"10.1200\/jco.2008.26.15_suppl.5024"},{"key":"24_CR20","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1073\/pnas.171076798","volume":"98","author":"MS Neshat","year":"2001","unstructured":"Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR. Proc Natl Acad Sci U S A 98:10314\u201310319","journal-title":"Proc Natl Acad Sci U S A"},{"key":"24_CR21","unstructured":"Oza AM et al (2005) A phase II study on temsirolimus (CCI-779) in patients with metastatic and\/or recurrent endometrial cancer. In: Proceedings of 17th symposium on molecules targets cancer therapy, Philadelphia, USA, 197 AB269, November 2005"},{"key":"24_CR22","first-page":"2887","volume":"9","author":"JM Peralba","year":"2003","unstructured":"Peralba JM, DeGraffenried L, Friedrichs W et al (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887\u20132892","journal-title":"Clin Cancer Res"},{"key":"24_CR23","doi-asserted-by":"crossref","first-page":"10320","DOI":"10.1073\/pnas.171060098","volume":"98","author":"K Podsypanina","year":"2001","unstructured":"Podsypanina K, Lee RT, Politis C et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70\/S6 kinase activity in Pten\u00b1 mice. Proc Natl Acad Sci US A 98:10320\u201310325","journal-title":"Proc Natl Acad Sci US A"},{"key":"24_CR24","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","volume":"22","author":"E Raymond","year":"2004","unstructured":"Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336\u20132347","journal-title":"J Clin Oncol"},{"key":"24_CR25","doi-asserted-by":"crossref","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (Epub ahead of print)","DOI":"10.1200\/JCO.2008.16.9847"},{"issue":"23","key":"24_CR26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","volume":"313","author":"SA Rosemberg","year":"1985","unstructured":"Rosemberg SA, Lotze MT, Muul ML et al (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23):1485\u20131492","journal-title":"N Engl J Med"},{"issue":"2","key":"24_CR27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","volume":"270","author":"CJ Sabers","year":"1995","unstructured":"Sabers CJ, Matrin MM, Brunn JJ et al (1995) Isolation of a protein target of FKBP 12-rapamycin complex in mammalian cells. J Biol Chem 270(2):815\u2013822","journal-title":"J Biol Chem"},{"issue":"suppl","key":"24_CR28","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025","volume":"25","author":"C Szczylik","year":"2007","unstructured":"Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol 25(suppl):Abstract 5025","journal-title":"J Clin Oncol"},{"key":"24_CR29","first-page":"122","volume":"12","author":"GV Thomas","year":"2006","unstructured":"Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia inducible factors determines sensitivity to inhibitors of mTOR in kidney cancer. Nad Med 12:122\u2013127","journal-title":"Nad Med"},{"key":"24_CR30","unstructured":"Verhoef G, Hess et al (2008) Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator\u2019s choice therapy. In: 13th congress of the European Hematology Association (EHA)"},{"key":"24_CR31","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE et al (2005a) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347\u20135356","journal-title":"J Clin Oncol"},{"key":"24_CR32","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","volume":"23","author":"TE Witzig","year":"2005","unstructured":"Witzig TE et al (2005b) Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347\u20135356","journal-title":"J Clin Oncol"},{"key":"24_CR33","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an antivascular endothelia growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"24_CR34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","volume":"8","author":"K Yu","year":"2001","unstructured":"Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8:249\u2013258","journal-title":"Endocr Relat Cancer"}],"container-title":["Recent Results in Cancer Research","Small Molecules in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-54490-3_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T13:44:12Z","timestamp":1676641452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-642-54490-3_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"ISBN":["9783642544897","9783642544903"],"references-count":34,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-54490-3_24","relation":{"is-part-of":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1007\/978-3-642-54490-3","asserted-by":"object"}]},"ISSN":["0080-0015","2197-6767"],"issn-type":[{"value":"0080-0015","type":"print"},{"value":"2197-6767","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]},"assertion":[{"value":"23 April 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}